Cardiology Rounds Team's Page

Good news for coffee drinkers--new observational data presented last week at EPI|PNAM 2010, the Cardiovascular Disease Epidemiology and Prevention and Nutrition, Physical Activity, and Metabolism 2010 Conference, suggests that multiple cups of Joe are associated with a lower risk of arrhythmias. [1]

"A lot of people think they have palpitations from coffee, and doctors commonly tell people not to drink it, but there are very few actual data, and the data that are availabl

… Continue

The first study to demonstrate that ticagrelor (AstraZeneca) therapy overcomes nonresponsiveness to clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Aventis) treatment has been reported [1]. In the RESPOND
trial, platelet inhibition in both clopidogrel responders and
nonresponders was significantly enhanced by switching to ticagrelor
therapy.

"The extremely low prevalence of high platelet reactivity in patients treated with ticagrelor provides a mechanism for the clinical

… Continue

Physicians attending the American College of Cardiology (ACC) 2010 Scientific Sessions/i2 Summit should
find it easier to pack up the things they learn at this year's meeting
and take them home to apply in their practices right away, according to
meeting chairs who say the focus of this year's meeting is
patient-centered care. That theme, which has been a yearlong focus for
ACC president Dr Alfred Bove, means that this year's
meeting--from the selection of late-breaking clin… Continue

Background Both dopamine and norepinephrine are recommended as first-line vasopressor agents in the treatment of shock. There is a continuing controversy about whether one agent is superior to the other.

Methods In this multicenter, randomized trial, we assigned patients with shock to receive either dopamine or norepinephrine as first-line vasopr

… Continue

Background— Recent studies have raised concerns about the reduced efficacy of clopidogrel when used concurrently with proton pump inhibitors (PPIs), but those studies may have overestimated the risk.

Methods and Results— We studied the potential for increased risk of adverse cardiovascular events among users of clopidogrel with versus without concurrent use of PPIs in 3 large cohorts of patients

… Continue